- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Long-term prognosis of children with steroid-dependent nephrotic syndrome following high-dose mizoribine therapy
-
- Yamada Akifumi
- Division of nephrology, Saitama Children’s Medical Center Department of Pediatrics, The Jikei University School of Medicine
-
- Fujinaga Shuichiro
- Division of nephrology, Saitama Children’s Medical Center
-
- Hara Taichi
- Division of nephrology, Saitama Children’s Medical Center
-
- Urushihara Yasuko
- Division of nephrology, Saitama Children’s Medical Center
-
- Hirano Daishi
- Department of Pediatrics, The Jikei University School of Medicine
-
- Ohtomo Yoshiyuki
- Department of Pediatrics, Juntendo Nerima Hospital
-
- Ida Hiroyuki
- Department of Pediatrics, The Jikei University School of Medicine
Bibliographic Information
- Other Title
-
- シクロスポリン投与前に高用量ミゾリビン療法を施行したステロイド依存性ネフローゼ症候群の長期的検討
Search this article
Description
Background: Recent studies showed that high-dose mizoribine (MZR) therapy may be effective in the management of children with steroid-dependent nephrotic syndrome (SDNS). However, long-term prognosis of the patients following the immunosuppressive agent remains unclear. Patients and methods: We retrospectively analyzed 12 patients with SDNS who received high-dose MZR prior to cyclosporine (CsA) administration. MZR was initiated at a single daily dose of 5 mg/kg administered after breakfast and adjusted to maintain 2-h post-dose MZR levels of approximately 3-5 μg/mℓ. Results: In all but one patient, treatment with MZR (mean MZR dose, 8.6 mg/kg/day; mean C2, 3.4 μg/mℓ) resulted in significant reduction of the mean prednisolone dose from 0.45 to 0.12 mg/kg/day and the mean relapse rate from 1.86 to 0.40 episodes/12 months. Of six patients who were able to discontinue high-dose MZR therapy, only one patient returned to SDNS and was re-treated with MZR during follow-up periods (median 4.2 years). Conclusion: High-dose MZR therapy may allow many patients with SDNS to avoid further toxic immunosuppressive agents such as CsA in the long term.
Journal
-
- Japanese journal of pediatric nephrology
-
Japanese journal of pediatric nephrology 28 (2), 140-144, 2015
The Japanese Society for Pediatric Nephrology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204340088064
-
- NII Article ID
- 130005108681
-
- ISSN
- 18813933
- 09152245
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed